Stillwater Capital Advisors Lowers stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Stillwater Capital Advisors reduced its stake in AbbVie Inc by 0.15% during the most recent quarter end. The investment management company now holds a total of 195,364 shares of AbbVie Inc which is valued at $11,626,112 after selling 299 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Apr 11, 2016.AbbVie Inc makes up approximately 3.37% of Stillwater Capital Advisors’s portfolio.

AbbVie Inc opened for trading at $59.55 and hit $59.74 on the upside on Friday, eventually ending the session at $59.51, with a gain of 0.39% or 0.23 points. The heightened volatility saw the trading volume jump to 46,60,835 shares. Company has a market cap of $95,885 M.

Other Hedge Funds, Including , Beese Fulmer Investment Management reduced its stake in ABBV by selling 1,400 shares or 7.43% in the most recent quarter. The Hedge Fund company now holds 17,439 shares of ABBV which is valued at $1,037,795. AbbVie Inc makes up approx 0.30% of Beese Fulmer Investment Management’s portfolio.Thompson Rubinstein Investment Management Inc Or boosted its stake in ABBV in the latest quarter, The investment management firm added 25,226 additional shares and now holds a total of 72,240 shares of AbbVie Inc which is valued at $4,226,040. AbbVie Inc makes up approx 1.74% of Thompson Rubinstein Investment Management Inc Or’s portfolio.Livingston Group Asset Management Co (operating As Southp… reduced its stake in ABBV by selling 662 shares or 4.29% in the most recent quarter. The Hedge Fund company now holds 14,783 shares of ABBV which is valued at $864,806. AbbVie Inc makes up approx 0.56% of Livingston Group Asset Management Co (operating As Southp…’s portfolio.Indiana Trust Investment Management Co boosted its stake in ABBV in the latest quarter, The investment management firm added 11,320 additional shares and now holds a total of 20,120 shares of AbbVie Inc which is valued at $1,177,020. AbbVie Inc makes up approx 0.65% of Indiana Trust Investment Management Co’s portfolio.

On the company’s financial health, AbbVie Inc reported $1.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 29, 2016. Analyst had a consensus of $1.12. The company had revenue of $6400.00 million for the quarter, compared to analysts expectations of $6382.82 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.89 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.